Pilot-Trans Network Core (PDTC/PDXNet)
Official title: Pilot-Trans Network Core
Funded at Wistar Institute · NIH-11397819 · Data updated 2026-11-12
A program that funds and guides new ideas within the PDTC and PDXNet to strengthen melanoma patient research networks and share findings with researchers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2017 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $146,585 |
| NIH project number | 5U54CA224070-08 |
| Project ID | NIH-11397819 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are researchers and clinicians involved in melanoma research who can contribute to and benefit from PDTC/PDXNet collaboration and pilot project funding.
✕Less likely to help
Patients may not directly benefit from participation in this program unless their research translates into clinical advances.
What this research studies
This grant supports a Pilot Core that invites high-quality pilot projects and coordinates cross-network collaboration among investigators studying malignant melanoma within the PDTC and PDXNet. It emphasizes transparent peer review, progress monitoring, and integration of funded pilots into ongoing program goals, with an eye toward publications and new funding. The focus is on building resources, technologies, and approaches that can advance melanoma research and potentially translate into better patient outcomes. Investigators must be active in PDTC functions, use core resources, and provide progress reports.
Why it matters
Potential benefit: If successful, this core could accelerate melanoma research progress and strengthen collaborative tools and resources that may lead to new treatments or improved trials for patients.
How similar studies have gone: Past pilot-core programs in research networks have led to publications and new collaborations, though direct patient treatment benefits depend on subsequent translational work.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Herlyn, Meenhard F — Wistar Institute
- Study coordinator: Herlyn, Meenhard F
Related research
Other NIH-funded projects on the same topics.
-
Immunomodulation to Fight Cancer Spread
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.